Innovation and new technologies in hydrogel wound dressings for treating diabetic foot ulcers: a twenty-year review

Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S184
Author(s):  
J.E. Ävila-Quiroga ◽  
V. Pinzön-Mora ◽  
V.A. Solarte-David ◽  
S.M. Becerra-Bayona ◽  
M.L. Luna-Gonzalez
Keyword(s):  
Diabetic Foot ◽  
New Technologies ◽  
Wound Dressings ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers

scholarly journals Application of 3D Bioprinting Technologies to the Management and Treatment of Diabetic Foot Ulcers

Biomedicines ◽  
2020 ◽  
Vol 8 (10) ◽  
pp. 441
Author(s):  
Chew Teng Tan ◽  
Kun Liang ◽  
Zong Heng Ngo ◽  
Christabel Thembela Dube ◽  
Chin Yan Lim
Keyword(s):  
Diabetic Foot ◽  
Skin Grafting ◽  
Current Treatment ◽  
Wound Dressings ◽  
Wound Management ◽  
Healthcare Sector ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers ◽  
3D Bioprinting ◽  
Skin Substitutes

Diabetes mellitus (DM) is a chronic metabolic disease with increasing prevalence worldwide. Diabetic foot ulcers (DFUs) are a serious complication of DM. It is estimated that 15–25% of DM patients develop DFU at least once in their lifetime. The lack of effective wound dressings and targeted therapy for DFUs often results in prolonged hospitalization and amputations. As the incidence of DM is projected to rise, the demand for specialized DFU wound management will continue to increase. Hence, it is of great interest to improve and develop effective DFU-specific wound dressings and therapies. In the last decade, 3D bioprinting technology has made a great contribution to the healthcare sector, with the development of personalized prosthetics, implants, and bioengineered tissues. In this review, we discuss the challenges faced in DFU wound management and how 3D bioprinting technology can be applied to advance current treatment methods, such as biomanufacturing of composite 3D human skin substitutes for skin grafting and the development of DFU-appropriate wound dressings. Future co-development of 3D bioprinting technologies with novel treatment approaches to mitigate DFU-specific pathophysiological challenges will be key to limiting the healthcare burden associated with the increasing prevalence of DM.

scholarly journals The Influence of Beliefs About Health and Illness on Foot Care in Ugandan Persons with Diabetic Foot Ulcers

2013 ◽  
Vol 7 (1) ◽  
pp. 123-132 ◽  
Author(s):  
Katarina Hjelm ◽  
Esther Beebwa
Keyword(s):  
Diabetic Foot ◽  
Self Care ◽  
Sub Saharan Africa ◽  
Wound Dressings ◽  
Care Process ◽  
Foot Ulcers ◽  
Care Seeking ◽  
Diabetic Foot Ulcers ◽  
Foot Care ◽  
Health And Illness

Diabetes mellitus is becoming pandemic, particularly affecting Sub-Saharan Africa, and the prevalence of complications is increasing. Diabetic foot disorders are a major source of morbidity and disability. Delay in the health care process due to patients’ beliefs may have deleterious consequences for limb and life in persons with diabetic foot ulcers. No previous studies of beliefs about health and illness in persons with diabetic foot ulcers living in Africa have been found. The aim of the study was to explore beliefs about health and illness among Ugandans with diabetic foot ulcers that might affect self-care and care seeking behaviour. In an explorative study with consecutive sample semi-structured interviews were held with 14 Ugandan men and women, aged 40-79, with diabetic foot ulcer. Knowledge was limited about causes, management and prevention of diabetic foot ulcers. Foot ulcers were often detected as painful sores, perceived to heal or improve, and led to stress and social isolation due to smell and reduced mobility. Most lacked awareness of the importance of complete daily foot care and seldom practised self-care. Health was described as absence of disease and pain. Many feared future health and related it to contact with nurses in the professional sector from whom they sought information, blood tests and wound dressings and desired better organised diabetes clinics offering health education and more opening hours. Many have an underutilised potential for self-care and need education urgently, delivered in well-organised diabetes clinics working to raise awareness of the threat and prevent foot ulcers.

scholarly journals DIABETIC FOOT ULCERS- OLD PROBLEMS, NEW TECHNOLOGIES

2018 ◽  
Vol 7 (12) ◽  
pp. 1493-1497
Author(s):  
Anuj Mahajan ◽  
Tejinderpal Singh ◽  
Anju Bhagtana ◽  
Aaina Malhotra
Keyword(s):  
Diabetic Foot ◽  
New Technologies ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers

scholarly journals Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0245652
Author(s):  
Franck Maunoury ◽  
Anaïs Oury ◽  
Sophie Fortin ◽  
Laetitia Thomassin ◽  
Serge Bohbot ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Diabetic Foot ◽  
Cost Savings ◽  
Wound Dressings ◽  
Sensitivity Analyses ◽  
Foot Ulcers ◽  
Base Case ◽  
Diabetic Foot Ulcers ◽  
Lifetime Horizon ◽  
Life Years

This study assesses the cost-effectiveness of Technology Lipido-Colloid with Nano Oligo Saccharide Factor (TLC-NOSF) wound dressings versus neutral dressings in the management of diabetic foot ulcers (DFUs) from a French collective perspective. We used a Markov microsimulation cohort model to simulate the DFU monthly progression over the lifetime horizon. Our study employed a mixed method design with model inputs including data from interventional and observational studies, French databases and expert opinion. The demographic characteristics of the simulated population and clinical efficacy were based on the EXPLORER double-blind randomized controlled trial. Health-related quality of life, costs, and resource use inputs were taken from the literature relevant to the French context. The main outcomes included life-years without DFU (LYsw/DFU), quality-adjusted life-years (QALYs), amputations, and lifetime costs. To assess the robustness of the results, sensitivity and subgroup analyses based on the wound duration at treatment initiation were performed. Treatment with the TLC-NOSF dressing led to total cost savings per patient of EUR 35,489, associated with gains of 0.50 LYw/DFU and 0.16 QALY. TLC-NOSF dressings were established as the dominant strategy in the base case and all sensitivity analyses. Furthermore, the model revealed that, for every 100 patients treated with TLC-NOSF dressings, two amputations could be avoided. According to the subgroup analysis results, the sooner the TLC-NOSF treatment was initiated, the better were the outcomes, with the highest benefits for ulcers with a duration of two months or less (+0.65 LYw/DFU, +0.23 QALY, and cost savings of EUR 55,710). The results from the French perspective are consistent with the ones from the German and British perspectives. TLC-NOSF dressings are cost-saving compared to neutral dressings, leading to an increase in patients’ health benefits and a decrease in the associated treatment costs. These results can thus be used to guide healthcare decisionmakers. The potential savings could represent EUR 3,345 per treated patient per year and even reach EUR 4,771 when TLC-NOSF dressings are used as first line treatment. The EXPLORER trial is registered with ClinicalTrials.gov, number NCT01717183.

Sign in / Sign up

Export Citation Format

Share Document